drugset
Drugs / ETB-DualNK-01
last change Mar 2026 re-read 3 minutes ago

ETB-DualNK-01

Cell therapy

Developed for
castration-resistant prostate carcinoma · prostate adenocarcinoma
Investigated by
Beijing Biotech

Trials 1

today NCT07641049 · Ph 1
2027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07641049 Mar 2026 → Mar 2027 expected castration-resistant prostate carcinoma, prostate adenocarcinoma Beijing Biotech Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ETB-DualNK-01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07641049 ↗
Modality Cell therapy “ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy” NCT07641049 ↗
Route Intravenous “Allogeneic dual-target antiPSMA/PSCA CAR-NK cells administered intravenously on Day 0” NCT07641049 ↗